[go: up one dir, main page]

WO1991001624A8 - Utilisation d'antagonistes du calcium pour le traitement de cicatrices - Google Patents

Utilisation d'antagonistes du calcium pour le traitement de cicatrices

Info

Publication number
WO1991001624A8
WO1991001624A8 PCT/US1990/004294 US9004294W WO9101624A8 WO 1991001624 A8 WO1991001624 A8 WO 1991001624A8 US 9004294 W US9004294 W US 9004294W WO 9101624 A8 WO9101624 A8 WO 9101624A8
Authority
WO
WIPO (PCT)
Prior art keywords
calcium antagonists
treating scars
scars
treating
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1990/004294
Other languages
English (en)
Other versions
WO1991001624A2 (fr
Inventor
Raphael C Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Priority to DE69007486T priority Critical patent/DE69007486T2/de
Priority to CA002059558A priority patent/CA2059558C/fr
Priority to AT90912115T priority patent/ATE102828T1/de
Publication of WO1991001624A2 publication Critical patent/WO1991001624A2/fr
Anticipated expiration legal-status Critical
Publication of WO1991001624A8 publication Critical patent/WO1991001624A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US1990/004294 1989-07-31 1990-07-31 Utilisation d'antagonistes du calcium pour le traitement de cicatrices Ceased WO1991001624A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69007486T DE69007486T2 (de) 1989-07-31 1990-07-31 Verwendung von calciumantagonisten für die behandlung von narben.
CA002059558A CA2059558C (fr) 1989-07-31 1990-07-31 Utilisation d'antagonistes du calcium pour traiter les cicatrices
AT90912115T ATE102828T1 (de) 1989-07-31 1990-07-31 Verwendung von calciumantagonisten fuer die behandlung von narben.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38760489A 1989-07-31 1989-07-31
US387,604 1989-07-31

Publications (2)

Publication Number Publication Date
WO1991001624A2 WO1991001624A2 (fr) 1991-02-21
WO1991001624A8 true WO1991001624A8 (fr) 2005-06-16

Family

ID=23530617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004294 Ceased WO1991001624A2 (fr) 1989-07-31 1990-07-31 Utilisation d'antagonistes du calcium pour le traitement de cicatrices

Country Status (5)

Country Link
EP (1) EP0485470B1 (fr)
JP (1) JP3149180B2 (fr)
CA (1) CA2059558C (fr)
DE (1) DE69007486T2 (fr)
WO (1) WO1991001624A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569678A (en) * 1989-07-31 1996-10-29 Massachusetts Institute Of Technology Control of wound scar production
ATE341316T1 (de) * 1992-07-20 2006-10-15 Massachusetts Inst Technology Kontrolle der wundvernarbung mit calmodulin- inhibitoren oder protein-kinase-c-inhibitoren
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
WO1994023748A1 (fr) * 1993-04-08 1994-10-27 The University Of Queensland Administration d'un agent vaso-actif et d'un agent therapeutique
FR2740341B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, d'etain, de zinc, de manganese, d'yttrium, de cobalt, de baryum, de strontium dans une composition pour la peau
US6525100B1 (en) 1998-08-03 2003-02-25 W. Jerry Easterling Composition and method for treating peyronie's disease and related fibrotic tissue disorders
US6627663B2 (en) 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
JP3157784B2 (ja) 1998-08-19 2001-04-16 新潟日本電気株式会社 電子写真感光体およびその製造方法
US7094431B2 (en) * 2000-10-12 2006-08-22 Mickey L. Peshoff Method of healing skin wounds in mammals and a composition therefor
JP4682129B2 (ja) * 2003-06-09 2011-05-11 アセンド セラピュティクス インコーポレイテッド ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
GB201119089D0 (en) * 2011-11-04 2011-12-21 Isis Innovation Treatment of musculoskeletal fibroproliferative disorders

Also Published As

Publication number Publication date
WO1991001624A2 (fr) 1991-02-21
CA2059558C (fr) 2002-11-12
EP0485470A1 (fr) 1992-05-20
JP3149180B2 (ja) 2001-03-26
DE69007486T2 (de) 1994-08-11
JPH05500045A (ja) 1993-01-14
EP0485470B1 (fr) 1994-03-16
DE69007486D1 (de) 1994-04-21
CA2059558A1 (fr) 1991-02-01

Similar Documents

Publication Publication Date Title
PH27372A (en) Acat inhibitors for treating hypercholesterolemia
AU3478289A (en) Treatment of fibrous materials
AU5869990A (en) Means for surgical treatment
GB8911970D0 (en) Method of treating fibrous materials
WO1991001624A8 (fr) Utilisation d'antagonistes du calcium pour le traitement de cicatrices
HU903302D0 (en) Process for the production of medical preparations containing calcium inhibitor for treating anxiety
AU5185790A (en) Treatment of tibial dyschondroplasia
US5011841B1 (en) Treatment of depression
AU6186490A (en) Treatment of fibrous materials
AU5953090A (en) Novel use of 1-phenyl-2-aminoethanol derivatives as healing agents
GB8920424D0 (en) Surgical dressing
AU3189989A (en) Process for the treatment of concrete
GB2215214B (en) Surgical dressing
AU624262B2 (en) Use of prophenytoin for treating stroke
AU7167591A (en) Treatment of hsv
GB2233340B (en) Treatment of organic slurry
RU2005047C1 (ru) Устройство дл обработки хрупких материалов
AU5857190A (en) Process for the treatment of used oil
EP0412938A3 (en) System for the treatment of contactlenses
GB8916394D0 (en) Method of treatment
ZA906306B (en) Use of prophenytoin for treating stroke
GB8903284D0 (en) Treatment of materials
CS202389A1 (en) Method of flat lignocellulosic materials treatment
ZA896545B (en) Process for the treatment of concrete
IE891751L (en) Treatment of arthritis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2059558

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990912115

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990912115

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990912115

Country of ref document: EP

D17 Declaration under article 17(2)a